Literature DB >> 8849550

Intraocular lens implantation in children in the West Bank and Gaza.

C A Kanawati1.   

Abstract

In order to evaluate the efficacy and safety of intraocular lens (IOL) implantation in paediatric aphakia, we reviewed the records of a consecutive series of 40 children, under 15 years of age, who had IOLs inserted for congenital and developmental cataracts between September 1990 and December 1992. Visual results and lens-induced complications were evaluated in 67 eyes with a mean follow-up of 27 months (range 12-38 months). In 52 eyes the cataract was removed by limbal lens aspiration and in 15 eyes by pars plicata lens aspiration. One-piece PMMA Sinskey-type posterior chamber implants were used in all cases. Sixty-three eyes had primary and 4 eyes secondary implants. Seventeen (49%) of 35 eyes with congenial cataract and 25 (78%) of 32 eyes with developmental cataract achieved a visual acuity of 6/18 or better. Marked anterior uveitis with pupillary membrane formation occurred in 9 (13%) of the 67 eyes. Visually significant posterior capsule opacification occurred in 5 (28%) of the 18 eyes with intact capsule. Our results demonstrate the suitability of IOL implantation in children from an area of low socioeconomic background, and suggest that IOL implantation is an effective and safe procedure for correction of paediatric aphakia. This may have implications for similar populations.

Entities:  

Mesh:

Year:  1995        PMID: 8849550     DOI: 10.1038/eye.1995.195

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  2 in total

1.  Visual recovery in unilateral traumatic pediatric cataracts treated with posterior chamber intraocular lens and anterior vitrectomy in Pakistan.

Authors:  R A Cheema; A D Lukaris
Journal:  Int Ophthalmol       Date:  1999       Impact factor: 2.031

2.  Use of intraocular lenses in children with traumatic cataract in south India.

Authors:  M Eckstein; P Vijayalakshmi; M Killedar; C Gilbert; A Foster
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.